Understanding joint lining changes on ultrasound in hemophilia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study uses ultrasound to check if thickened joint lining (synovium) in people with severe hemophilia is a sign of active inflammation or just a harmless leftover. It may help doctors decide whether to treat or watch these joints.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male.
- You have severe hemophilia A or B.
- You are 12 years or older.
- You take regular hemophilia medication to prevent bleeds (prophylaxis).
- An ultrasound has shown some thickening of the joint lining (synovium) in at least one of your ankles, knees, or elbows.
- You have not had a major bleed in that joint in the last 3 months or a minor bleed in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study looks at how hemophilia A affects joint health, balance, and quality of life in adults. Researchers will assess your joints and balance to understand the relationship between joint damage and everyday function.
This study looks at how many adults with moderate or severe hemophilia A have inflammation in their joints (synovitis). It aims to better understand joint health in people with hemophilia A, including those with inhibitors or joint replacements.
This study uses ultrasound to check the health of your joints. It aims to see if people with mild hemophilia have joint problems even without frequent bleeding, which could help guide future treatment.
This study uses ultrasound to check if joints that are currently healthy stay healthy in people with hemophilia A who are taking emicizumab (Hemlibra) as their regular treatment. It aims to see if this treatment helps prevent joint damage over time.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.